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Gastrointestinal Stromal Tumors (GIST) are sarcomas driven by gain-of-function mutations
of KIT or PDGFRA. Although, the introduction of tyrosine kinase inhibitors has
dramatically changed the history of this disease, evidences emerge that inhibition of KIT or
PDGFRA are not sufficient to cure patients. The developmental pathway Notch has a critical
role in the cell fate, regulating cell proliferation and differentiation. Dysregulation of Notch
pathway has been implicated in a wide variety of cancers functioning as a tumor promoter or
a tumor suppressor in a cell context dependent manner.
Given that Notch activation deregulates the morphogenesis of mesenchymal cells in the GI
track, that Notch acts as a tumor suppressor in neuroendocrine tumors, and finally that the
cell of origin of GIST are the Interstitial Cell of Cajal that arise from a mesenchymal origin
with some neuroendocrine features, we hypothesized that Notch pathway signaling may play
a role in growth, survival and differentiation of GIST cells. To test this hypothesis, we
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genetically and pharmacologically manipulated the Notch pathway in human GIST cells. In
this study, we demonstrated that constitutively active intracellular domain of Notch1 (ICN1) expression potently induced growth arrest and downregulated KIT expression. We have
performed a retrospective analysis of 15 primary GIST patients and found that high mRNA
level of Hes1, a major target gene of Notch pathway, correlated with a significantly longer
relapse-free survival.
Therefore, we have established that treatment with the FDA approved histone deacetylase
inhibitor SAHA (Vorinostat) caused dose-dependent upregulation of Notch1 expression and
a parallel decrease in viability in these cells. Retroviral silencing of downstream targets of
Notch with dominant negative Hes-1 as well as pharmacological inhibition of Notch
pathway with a γ-secretase inhibitor partially rescued GIST cells from SAHA treatment.
Taken together these results identify anti-tumor effect of Notch1 and a negative cross-talk
between Notch1 and KIT pathways in GIST. Consequently, we propose that activation of
this pathway with HDAC inhibitors may be a potential therapeutic strategy for GIST
patients.	
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Chapter 1. Introduction and Background
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1. Gastrointestinal stromal tumors as a paradigm in translational research
Gastrointestinal stromal tumors (GIST) are soft tissue sarcomas primarily occurring in the
stomach (60%) or small intestine (35%), but may also affect the colon, rectum, esophagus or
retroperitoneum [1, 2]. Their incidence has been estimated to be between ten and 15 cases
per million people, giving approximately 4,000 to 5,000 new cases annually in the United
States [3-5]. The median age at diagnostic is 60 years [1] and GISTs rarely affect children
with less than 3% of cases before the age of 21 years [6]. The term ‘GIST’ was introduced
by Mazur and Clark in 1983 to distinguish specific stromal tumors from other mesenchymal
neoplasms of the Gastrointestinal (GI) tract such as leiomyosarcomas (LMS), leiomyomas,
leiomyoblastoma, and schwannomas [7]. At that time, it was clear that GIST had a specific
natural history and was generally resistant to conventional chemotherapy and radiation, with
less than 5% of response in advanced patients [8, 9]. Although some old studies reported
higher response rates, it is possible to speculate that old studies that have reported higher
response rates to conventional chemotherapy in GIST included, in fact, some LMS patients.
Prior the area of target therapies, the majority of GIST patients developed recurrences within
five years despite complete surgical resection, preferentially into the peritoneal cavity or the
liver [1]. In this population, the median survival was only 15 months. Long term survivals
were rare, for example, a study from MD Anderson Cancer Center (MDACC) has found
that no more than 10% of patients were disease free after forty months of follow-up [10].
The origin of GIST remained controversial until 1998, when Kindblom and colleagues from
Göteborg University, observed striking morphological and immunophenotypic resemblance
between GIST cells and the Interstitial Cells of Cajal (ICC), which serve as the pacemaker
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cell of the gastrointestinal tract [11]. Ultrastructural similarities, including filopodia-like
cytosplasmic projections, large mitochondria, large Golgi, associated with strong
immunoreactivity for CD117 (KIT) and CD34 antibodies provided evidences that GIST are
likely to arise from ICC or ICC precursors. The same year, Hirota and colleagues, made the
seminal discovery that the large majority of GIST contain activating mutations in the protooncogene KIT [12]. In this study, on 6 patients with GIST, 5 harbored mutation in the juxtamembrane domain of KIT. These mutations constitutively activated KIT receptor without
the requirement of the stem cell factor (SCF) ligand. These ‘gain-of-function’ mutations
proved to be oncogenic as they induced malignant transformation in a lymphoid cell model,
suggesting a major role of KIT mutations in GIST development. The functional key role of
KIT mutations in GIST has been since supported by multiple lines of evidence. First, the
activated phosphorylated KIT is found by immunohistochemistry in virtually all GIST
samples [13]. Then, rare patients with germ-line mutations of KIT develop multiple familial
GIST [14-17]. Engineered mouse models expressing KIT mutations develop GIST-like
tumors [18, 19]. And lastly, the inhibition of KIT with imatinib resulted in a decrease of
proliferation of GIST [20]. These findings allowed a major paradigm shift in GIST treatment
with the possibility to target a specific molecular abnormality resulting in an unprecedented
clinical success of a targeted therapy in solid tumor.

2. Oncogenic mutations in GIST
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The proto-oncogene KIT is located on chromosome 4q12 and encodes for a type III
transmembrane receptor tyrosine kinase. The gene KIT was first cloned in 1987 as the
homolog of the Hardy-Zuckerman feline sarcoma virus oncogene v-KIT [22]. The protein of
145 kilodaltons contains five extracellular immunoglobulin domains involved in ligand
binding and subsequent homodimerization, a single transmembrane domain, a
juxtamembrane domain with inhibitory functions, a kinase domain (ATP binding pocket and
activation loop) separated by a kinase insert and a carboxy-terminal tail region (Figure 1)
[22].

Figure 1. Schematic illustration of the gene and protein structure of KIT
KIT is located on chromosome 4q12 and contains 19 exons that encodes for an extracellular
ligand-binding domain, a juxtamembrane region, an ATP binding site (tyrosine kinase I), a
kinase insert and an activation loop (tyrosine kinase II).
In normal conditions, SCF binds KIT receptor and activates the kinase domain through
transphosphorylation of tyrosine residues [23, 24]. Downstream signaling effectors includes
the three following pathways: the phosphatidylinositol 3’-Kinase (PI3K), the mitogenactivated protein Kinase (MAPK) and Janus kinase/ signal transducers and activators of
4	
  
	
  

transcription (JAK/STAT) pathways [13, 25, 26]. AKT activation through PI3K, regulates
multiple target proteins such as Bad, MDM2, p27, FOXO, and mTOR, leading protein
translation, survival and proliferation. MAPK pathway activates transcription factor
including MYC, ELK, CREB, JUN and FOS (Figure 2).

Figure 2. KIT and PDGFRa signaling in GIST
KIT activation by ligand binding or gain-of-function mutation, results in activation of
RAS/RAF, PI3K and STAT pathways. The signal amplification leads changes in gene
expression through MYC, ELK, CREB, JUN, ETV1 and FOS. In parallel, AKT activation
modifies protein translation, cell cycle entry and apoptosis.	
  
In GIST, gain-of-function mutations of KIT result in kinase activation in absence of ligand.
The gene contains several hotspots, the majority of mutations occuring in exon 11. Those
mutations disrupt the juxtamembrane domain, forcing the kinase domain to switch into the
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active conformation [27]. Mutations consist of substitutions, deletion, and insertions and are
found in two thirds of GIST patients [28, 29]. The second most frequent mutations are in
exon 9 that encodes the extracellular domain of KIT and affect between 8 to 12 % of GIST
patients [30]. In presence of these mutations, the conformation of KIT changes to mimic the
homodimerization that occurs after ligand binding [24]. It is important to realize that
mutations in exon 9 imitate wild-type KIT activation resulting in a more resistant phenotype.
Clinically, exon 9 mutations are found preferentially in the small and large intestine whereas
exon 11 mutations are commonly seen in the stomach [31]. Uncommon primary mutations
(<2%) have been observed in the kinase domain (the ATP binding domain or the activation
loop) [32]. Of the GIST that not harbor KIT mutation, approximately 30% have a mutuallyexclusive activating mutations of the gene that encode for the receptor for platelet-derived
growth factor-alpha (PDGFRA) [33-36]. PDGFRA is a homologue of KIT and is located in
adjacent loci on chromosome 4q. This protein is also a tyrosine kinase receptor with
comparable functions. Mutations in PDGFRA occur in the juxtamembrane domain (exon
12), the ATP binding domain (exon 14) or the activation loop (exon 18). It has been reported
that GIST lacking KIT or PDGFRA mutations may have mutations in BRAF [37].
Additionally, defects in succinate dehydrogenase (SDH) complex caused by germ-line
mutations in SDH genes have been recently described in KIT or PDGFRA wild-type familial
GIST patients [38, 39].

3. Chromosomal alterations in GIST
Although KIT or PDGFRA mutations play a key function during the initiation and
development of GIST, other molecular alterations have essential roles during tumor
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progression. This is illustrated by the fact that patients with germline KIT mutations develop
familial GIST only after the age of 40 years indicating that though the mutation was present
since birth, this time was required to acquire additional genomic aberrations [17, 40]. An
additional argument is the description of ‘micro-GIST’ of less than 10 mm in size that are
frequently found in the general population after surgery or during autopsy (between 2.9-35%
of all patients) [41-44]. These micro-GIST appear inactive but harbor oncogenic KIT
mutations indicating that these mutations alone may be insufficient for complete tumor
progression.
Investigators have found that almost all adult GIST have cytogenetic aberrations [45, 46]. In
GIST, losses of chromosomes are more frequent than gains [47]. In particular, loss of
chromosome 14q, 1p and 22q appear to be frequent in GIST, observed in 40-67% [48-52].
This suggests that these three chromosomal regions may contain tumor suppressor genes
important in malignant transformation of GIST. Clinically, the loss of 1p is most likely to be
found in intestinal GIST and associated with aggressive clinical outcomes where the loss of
14p is more characteristic of gastric tumor and favorable prognosis. Additional losses on
chromosomes, 9p, 11p, 13q, 15q and 17p have been also reported and are associated with
malignancy [47]. Gains touch preferentially chromosomes 8q, 3q and 17q [53, 54]. Not
surprisingly, accumulation of chromosomal alterations correlated with a worse prognosis
[54]. Based on this observation, a recent study has proposed a gene signature on ‘genome
complexity’ to classified low and high risk GIST patients [55].
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4. Epigenetic alterations in GIST
The contribution of DNA methylation in the GIST malignancy has been suggested. In one
study, the hypomethylation of long interspersed nuclear element one (LINE-1), a surrogate
for global methylation, correlated with aggressiveness of GIST as well as chromosomal
unbalance [56]. In general in tumors, the global hypomethylation observed in repetitive
sequences coexists with a regional hypermethylation of CpG islands within specific gene
promoter regions [57, 58]. In GIST, a genome-wide DNA methylation analysis of GpC
islands has identified the hypermethylation of REC8, PAX3 and p16 promoter regions and a
correlation with worse prognosis [59].
The role of small non-coding RNAs in the development of GIST remains unclear but initial
data indicate that miR-221, miR-222 and miR-494 are down regulated in GIST and may
negatively regulate KIT expression [60, 61]. On the other hand, upregulation of miR-196a
was shown to drive malignant progression in GIST [62]. Additionally, our team has recently
presented data indicating that Imatinib exposure is associated with differential miRNA
expression profiles in GIST patient samples. In particular, a miRNA-449b increase was
noted and appeared to target the pRb-E2F1 pathway [63].
	
  

5. Quest for the origin: The Interstitial Cells of Cajal
The recent success in the management of GIST has been the accomplishment of more than a
century of research. At the end of the XIX century, the Spanish pathologist Santiago Ramón
y Cajal using staining with silver chromate and methylene blue identified interstitial cells
within the muscular layers of the GI wall [64, 65]. In his crucial work, he hypothesized that
these cells formed a complex system at the interface between the autonomic nervous system
and the smooth muscle of the GI tract [66]. This initial description was followed early by the
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intuition that these cells referred as ‘the interstitial cells of Cajal’ represented pacemaker
cells of the GI track similar to the pacemaker cells of the heart [67, 68]. Nevertheless, the
rigorous scientific demonstration of a pacemaker function came decades later with the
development of murine models where ablation of ICC resulted in suppression of the
electrical slow wave activity [68-71]. A breakthrough came when investigators found that
ICC expressed the receptor tyrosine kinase KIT (CD117) [72, 73]. This discovery gave a
tremendous opportunity to gain insight of into the biology of ICC [73, 74]. Developmental
studies that used to rely only on ultrastructure analysis became much powerful [75, 76].
Using KIT antibodies, it was now possible to follow the development of ICC within the GI
track and determined their embryological origin [77]. With an elegant quail and chick
chimeric model, a study suggested that ICC derived from mesenchymal precursors instead
of neural crest cells as previously thought [78]. Moreover, the lack of neural crest markers
gives additional arguments in favor of a mesodermal origin. Immunohistochemical studies
and confocal images using KIT antibodies revealed different types of ICC [79, 80]. The two
main ICC are the intramuscular ICC (ICC-IM) within the circular and longitudinal muscle
layers mediating neurotransmission and the myenteric ICC (ICC-MY) surround the neuronal
myenteric plexus and generating electrical slow waves (Figure 3). These two populations of
ICC regulating electrical and secretory signals in the muscular layers confirm remarkably
the Cajal’s initial vision that the interstitial cells are a complex network at the interface of
the nervous system and the smooth muscle tissue.
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Figure 3. Schematic depicting the localization of ICC through the gastrointestinal wall
layers
Cartoon showing localization of Intra-muscular ICC (ICC-IM) and Myenteric ICC (ICCMY) throughout the GI tract; MP myenteric plexus.
	
  
As mentioned earlier, the initial observations done in 1998 that GIST cells and ICC shared
phenotypical similarities leading the hypothesis that ICC are the cell-of-origin of GIST has
been confirmed by the development of genetically engineered mice model expressing KIT
mutations. In these mice ICC hyperplasia and GIST-like tumors were observed [18, 19].
Additionally, several studies have shown that ICC and GIST have similar gene expressions,
in particular with high expression of nestin, DOG1, PKCθ, Ano1, and ETV1 [80-86].
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Importantly, many studies have revealed that GIST expressed a neuroendocrine phenotype
suggesting a neuroendocrine differentiation [87, 88].

In particular, specific hormone

production such as synaptic vesicle protein 2 (SV2), synapsine 1, synaptobrevin,
amphiphysin and ghrelin have been found in GIST. Furthermore, ultrastructural studies by
electron microscopy showed numerous clear vesicles similar to synaptic-like microvesicles
(SLMV).
In addition of ICC, KIT is highly expressed is mast cells, melanocytes, germ cells and
hematopoietic progenitors [21]. As a result, KIT has critical functions for the developmental
processes of melanogenesis, gametogenesis and haematopoiesis.

6. Association with other primary malignancies
GIST can be associated with other primary tumors; in particular, in the well characterized
hereditary conditions such as Carney’s triade (gastric GIST, paraganglioma, and pulmonary
chondroma), Carney-Stratakis’s dyad (paraganglioma and GIST) and Neurofibromatosis
type 1 [89-91]. Nevertheless, outside these syndromes, our group reported that GIST may
often be associated with other neoplasms, in particular, gastric, genitourinary and other
sarcomas [92]. By studying 783 patients with GIST from MDACC during a 12 year followup, we found that approximately 20% of patients developed additional cancers, a higher
percentage than that expected in the general population. In a subsequent study, using a large
international cohort including 10 institutions, we identified and described a new syndrome
that associated GIST with Desmoid Tumor (DT) [93]. With a statistical analysis, we showed
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that the associations between GIST and DT were not random. More details of this study are
provided in the appendix of this dissertation.

7. Targeted therapy in GIST
The identification of KIT activation through mutations as the primary oncogenic mechanism
driving GIST offered a tremendous therapeutic opportunity. Indeed, imatinib mesylate (IM)
(Gleevec), a tyrosine kinase inhibitor (TKI) had been developed to inhibit the fusion kinase
BCR-ABL caused by the Philadelphia chromosome translocation in patient with chronic
myelogenous leukemia (CML) but have also showed activity against KIT and PDGFR-a [94,
95]. The IC50 of this molecule is 0.1 µM for KIT. IM is orally available, well absorbed
with a bioavalability of 98%, and metabolized by cytochrome P450 [96]. The first report of
clinical response with imatinib in GIST was published in April, 2001. The article described
the case of a remarkable response in a 50-year-old patient with metastatic GIST [97].
Following the report, clinical trials were launched and established the efficacy and safety of
imatinib in a record time. Clinical efficacy results for patients with advanced GIST from
clinical trials are detailed in Table 1. In February 2002, the US Food and Drugs
Administration (FDA) approved imatinib for treatment of patients with metastatic and
unresectable GIST [103].
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Study
EORTC
Phase I
US B2222
Phase II

Year

2001

N

EORTC
Phase III
Intergroup
S0033
Phase III

Response
Rate (%)

36

400-1000

56

73

400

50

2-year PFS
(%)

not reported

2003

Ref
van Oosterom et
al.[98]

48

2002

Demetri et al.[99]
74

EORTC
Phase II

IM dose
(mg)

600

58

27

800

73 (1-year
70 PFS)

473

400

50

52
Verweij et al.[100]
44

2004

Verweij et al.[101]
473

800

51

52

345

400

45

41

2008

Blanke et al.[102]
349	
  

800	
  

45	
  

46	
  

Table 1. Efficacy results from clinical trials in patients with advance GIST.
IM : imatinib, PFS: Progression Free survival.
The initial response to imatinib is observed in up to 80% of patients but varies depending
upon the mutation. Patient harboring a KIT exon 11 mutation experience a significantly
higher response rate and a longer relapse free survival and overall survival than patient with
wild-type tumor or exon 9 mutation [107, 108]. Despite the dramatic clinical success, the
long-term efficacy of imatinib is limited by the development of resistance and tumor
progression. Secondary resistance to imatinib after initial response is commonly caused by
secondary mutations of KIT, decreasing imatinib-binding and restoring KIT pathway
activity [109-112]. These mutations are concentrated in two ‘hotspots’: the ATP binding
domain pocket, encoded by the exon 13 and 14, and the activation loop encoded by the exon
17 and 18. Molecular and functional analyses of the different types of secondary mutations
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have provided a better understanding of structural events that are taking place [113-115].
These mutations are different but they all affect the 3 dimensional structure of KIT leading
to alteration of binding with imatinib.
The use of imatinib in adjuvant setting following complete resection of primary GIST has
been subsequently approved by the FDA for delayed tumor recurrence in patients at high
risk [104]. The recent result from a controlled trial presented by the Scandinavian Sarcoma
Group demonstrated that the RFS was better for a 3 years adjuvant treatment with IM than 1
year [105, 106]. As a result, IM 400mg/day for 3 years duration after surgery become the
new standard for high-risk patients. The optimal duration of adjuvant treatment remains
unknown but a large increase in relapse was observed after IM discontinuation supporting
the idea that an even longer duration may have a clinical benefit.
In the case of imatinib-refractory GIST, the second line TKI, Sunitinib malate (Sutent), is
the only FDA-approved treatment, but with limited clinical benefit prior to disease
progression [116]. Other TKIs, such as nilotinib (Tasigna), sorafenib (Nexavar), dasatinib
(Sprycel), regorafenib (Stivarga), crenolanib, masitinib are currently tested but due to TKI
cross-resistances, are unlikely to have a major clinical impact on resistant GIST [117]. For
those patients, it is crucial to find alternative strategies beyond KIT inhibition. The present
work proposes to evaluate, in vitro, the role of alternative pathways in the biology of GIST
cells with the ultimate objective to develop new therapeutic options to treat this tumor.

8. Notch pathway in normal development
Notch signaling is an extremely evolutionally conserved pathway that contributes in the
normal development of multicellular organisms by influencing cell-fate decisions during
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embryogenesis and postnatal development [118, 119]. In 1917, Thomas Hunt Morgan was
the first to described fruit flies with ‘notched’ wings, following two years later by the
description of a mutation causing this phenotype in a gene termed Notch [120, 121]. It is
only sixty years later that the fly Notch gene was cloned simultaneously by the teams of
Artavanis-Tsakonas and Young [122, 123]. The gene encodes a large transmembrane
polypeptide translated as a full-length protein but subsequently cleaved in the trans-Golgi by
a furin-like convertase to create a non-covalent heterodimeric receptor [124]. The
extracellular domain contains several Epidermal Growth Factor (EGF)-like domains and
cysteine-rich Lin12/Notch repeats (LNR). The cytosplamic part contains a RAM domain, six
ankyrin repeats (ANK), two nuclear localization sequences (NLS), a transcription
transactivation domain (TAD) and a C-terminal PEST sequence (Figure 4) [125, 126]. Two
ligands for the Notch receptor have been described in Drosophila melanogaster, delta and
serrate. In mammals, the Notch family contains four receptors (Notch1, Notch2, Notch3,
Notch4) and five ligands (delta-like-1-3-4 and Jagged-1-2) [127-131]. The activation of
Notch pathway is initiated by the ligand-receptor binding that changes the receptor
conformation. This three dimensional modification allows two consecutive proteolytic
cleavages, first by metalloproteases (ADAM10 or ADAM17) and then a γ-secretase
complex [132]. The γ-secretase complex is composed by the five following subunits:
nicastrin, presenillin1 and 2, Pen-2 and Aph1 [133, 134]. These cleavages allow the release
of the intracellular domain of Notch (ICN) into the cytoplasm. The ICN translocates to the
nucleus and attaches to the transcription factor CSL. In parallel, ICN recruits the coactivators mastermind-like (MAM) and histone acetyltransferase p300 to remove the
inhibitory effect of CSL and active the transcriptional activity of Notch targets genes (Figure
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4 ) [135]. The best characterized Notch targets are from the Hes family (Hairy and Enhancer
of Split) transcription factors which are basic helix-loop-helix repressors [136, 137].
Importantly, in addition of this canonical pathway, several lines of evidences indicate the
existence of CSL independent Notch signaling [138, 139]. In physiological conditions, the
Notch pathway participates to balance homeostasis via the control of cell-fate decisions,
maintenance of undifferentiated state or promotion of differentiation depending on the cell
context [140]. For example, a forced Notch signaling, in vivo, has shown to prevent
neurogenesis differentiation and to maintain neural stem-cells. Conversely, in skin, Notch
activation enhances terminal differentiation and cell-cycle arrest [141-143]. In the digestive
tract, a recent study has shown that constitutive Notch activity induced mesenchymal cell
loss and deregulated morphogenesis indicating a probable role of Notch in the development
of digestive tract mesenchyme [144].
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Figure 4. Simplified view of Notch signaling
A. structure of Notch1 proteins, includes epithelial-growth factor (EGF) like repeats,
Lin12/Notch repeats (LNR), heterodimerization domain (HD), RAM domain, two nuclear
localization signals (NLS), six ankyrin repeats (ANK), trans-activation domain (TAD) and a
PEST sequence. B. canonical Notch signaling is activated following ligand-receptor
interaction. Two cleavages mediated by metalloproteases and the γ-secretase complex
liberate the intracellular domain of Notch (ICN) in the cytoplasm. Before Notch activation
CSL is bound to DNA with co-repressor (CoR). Then ICN translocates into the nucleus,
binds CSL and recruits co-activators (HAT, histone acetyltransferase; MAM, mastermindelike; SKIP, ski-interaction protein) which lead transcriptional activation of Notch target
genes. The signal ends by ubiquitylation (Ub) of ICN and proteasomal degradation.
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9. The oncogenic role of Notch signaling
The oncogenic function of Notch was first described in T-cell acute lymphoblastic
leukemias (T-ALL). A rare translocation fuses the chromosome 7 and 9 that result in a
juxtaposition of the T-cell receptor β (TCRβ) gene with a truncated Notch1 gene [145, 146].
This translocation occurs in <1% of T-ALL cases, and results in expression of ICN1 that
leads to activation of the Notch pathway. The oncogenic role of Notch was further
confirmed by the fact that mice transplanted with hematopoietic progenitor cells expressing
ICN1 developed T-ALL [147]. In addition, it has been observed that proviral integration, in
particular the Moloney murine leukemia virus, into Notch genes may also result in T-cell
leukemia [148, 149]. Nevertheless, the definitive clinical relevance of Notch deregulation in
T-cell malignancy was confirmed 13 years later by the description of gain-of-function
mutations in Notch1 occurring in more than 50% of T-ALL [150]. These mutations affect
the heterodimerization domain and the PEST domain increasing a ligand-independent
cleavage and ICN1 stability, respectively, resulting in activation of Notch pathway in both
cases. Furthermore, a recent whole-genome sequencing analysis of chronic lymphoblastic
leukemia (CLL) has found recurrent activating Notch1 mutations in the PEST domain [151].
Although these mutations were less frequent than in T-ALL, they were associated with poor
prognosis of CLL.
In solid tumors, the oncogenic role of Notch was originally described in mouse mammary
tumor virus (MMTV) breast cancer model where retroviral insertions adjacent of Notch4
(int3) transform mammary cells [152]. In addition, Notch1 has also been found to function
as an oncogene in mice breast tumor models [153]. In human breast carcinomas, studies
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reported a high expression of Notch1, Notch ligands and Hes-1 associated with poor overall
survival [154, 155].
In non-small cell lung cancer (NSCLC), gain-of-function mutations of Notch1 and a loss of
Numb, an inhibitor of the Notch pathway, are frequently observed and correlated with poor
clinical outcomes [156]. Notch3 may also have a role, as a study reported that 40% of
NSCLC over-expressed Notch3 [157]. Additionally, inhibition of the Notch3 using a
dominant-negative or by γ-secretase inhibiton, reduced growth in soft agar and increased the
apoptosis. Similarly, in pancreatic cancer, activation of Notch pathway is frequently found
in patient samples and seems involved in tumor initiation and maintenance [158, 159].
Specific silencing of Notch1 or γ-secretase inhibition reduced pancreatic tumor cell growth
[160]. Additional studies have implicated Notch pathway in the carcinogenesis, tumor
maintenance and drug resistance in other solid tumors including colorectal, cervical, ovarian
cancers and melanomas [161-170].
Several studies have indicated that the molecular basic for the oncogenic role of Notch may
be caused by cross-talk with other pathways including Her2, phophatidylinositol 3-kinase /
AKT, Ras, p53 and β catenin / Wnt signaling [171-175]. These interactions promote various
oncogenic roles such as cell cycle entry, inhibition of apoptosis, regulation of angiogenesis,
and epithelial to mesenchymal transformation [176].

10. The tumor suppressive role of Notch signaling
From studies on the skin, researchers started to understand that the role of Notch pathway is
not exclusively oncogenic but may suppress tumors in some tissues. Indeed, expression of
Notch receptors and ligands induced cell-cycle arrest and terminal differentiation in the skin
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[141, 143, 177]. In consequence, mice with tissue-specific ablation of Notch1 resulted in
skin hyperplasia and spontaneous basal-cell carcinoma tumors [178]. Consistent with this
observation, the expression of Notch1, Notch2 and Jag1 are low in human basal cell
carcinomas. In addition of basal cell carcinomas, two high-throughput next generation
sequencing studies fortuitously revealed that 10 to 15% of patients with squamous cell
carcinomas of the head and neck (HNSCC) arbor inactivating mutations of Notch. In
addition, loss of heterogeneity (LOH) at the Notch1 locus was detected in some tumors
analyzed for gene copy number resulting in inactivation of both allele, providing evidence
for an important tumor suppressor effect of Notch1 in HNSCC [179, 180].
A good example of the versatility of Notch signaling in carcinogenesis is in lung cancer. In
this organ the impact of Notch pathway is predictable by a dichotomy between
neuroendocrine and non-neuroendocrine lung tumors. In contrast with what is observed in
NSCLC, in small-cell lung cancer (SCLC) cell growth is inhibited by an over-expression of
activated Notch1 and Notch2 [181, 182]. Transduction of intracellular Notch1 leads to an
increase in Hes1, down-regulation of Mash1 and a potent G1 arrest with p21 induction. In
other neuroendocrine tumors (NET) such as carcinoid and medullary thyroid cancer, Notch
signaling is minimally present and several observations strongly support a tumor suppressor
role for the Notch pathway [183-185]. Finally, the group of Dr. Zweidler-McKay has
reported that in B cell malignancies as well as in neuroblastoma, Notch can act as a tumor
suppressor [186-188]. In those cell lines, expression of constitutively active, truncated forms
of the 4 Notch receptors (ICN1-4) as well as HES genes inhibited growth and induced
apoptosis. 	
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11. Notch pathway in sarcomas
Given that the Notch pathway plays a pivotal role in the development of the mesoderm,
different groups have recently studied the deregulation of this pathway in the
sarcomagenesis. As it is the case for other malignancies, the role of Notch in sarcomas is
highly contingent on the cellular context (Table 2). We provide in this paragraph a
comprehensive review of Notch pathways in sarcomas.

Sarcomas

Effect

Mechanisms
Notch1 inhibition reduces proliferation, and
promotes differentiation in vitro and in vivo
Notch3 inhibition reduces cell growth in vitro
and in vivo

Rhabdomyosarcoma

Ewing's sarcoma

Osteosarcoma

Oncogene

Tumor
suppressor

Oncogene

Notch inhibition via dnMAM reduces
invasiveness and mobility in vitro
Hes 1 reverses cellular quiescence and supress
differentiation in vitro
Activation of Notch1 inhibits cell proliferation in
vitro
Activation of Notch1, 2, 3, Jag1 inhibits cell
proliferation in vitro
Expression of Notch3, Jag1 or Hey1 Induces p53
and p21 in vitro
HES1 increases invasion and metastasis
Inhibition via CBF1 si RNA suppresses growth
and induces p21 in vitro and in vivo
Inhibition via dnMAM decreases tumor growth
in vivo

Ref
Belyea et al, [189]
Raimondi et al, [190]
Roma et al, [191]
Sang et al, [192]
Baliko et al, [193]
Bennani-Baiti et al,
[194]
Ban et al, [195]

Zhang et al,
Tanaka et al, [196]
Engin et al, [197]

Angiosarcoma

Tumor
suppressor

Notch1 knockout mice develop angiosarcoma in
the liver

Dill et al, [198]

Undifferentiated
pleomorphic
sarcoma

Oncogene

Inhibition of Notch decrease self-renewal in
vivo

Wang CY et al,[199]

Table 2. Implication of Notch pathway in sarcomas.
A computational search on PubMed was performed using the keywords: Sarcoma*& Notch
(September 1st, 2012). On the 81 abstracts evaluated 11 studies were found to be relevant.
11.1.

Notch pathway in Rhabdomyosarcomas
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Rhabdomyosarcoma (RMS) is the most frequent type of soft tissue sarcoma in children.
These tumors are divided in two main histologic subtypes: embryonal (60%) and alveolar
(20%) [200, 201]. Although the exact cell of origin remains uncertain, it is accepted that
RMS arise from skeletal muscle precursors that failed to differentiate. In normal
myogenesis, Notch pathway inhibits differentiation and promotes stem cell maintenance
[202-204]. The first report implicating Notch in RMS tumorigenesis came from a study
showing that Hes1 controlled the reversibility of cellular quiescence. In this study, Hes1
mRNA was increased in 21 primary RMS tumors in comparison with skeletal controls.
Inactivation of Hes1 using a dominant negative Hes1 or a gama-secretase inhibitor (GSI) led
to differentiation and inhibited proliferation of RMS cells [192]. Subsequent studies
confirmed the role of Notch pathway in RMS tumorigenesis in vivo, by showing that
inhibition of Notch via Notch1 shRNA or by GSI decreased tumor growth [189]. The
pathway has also been implicated in RMS mobility and invasiveness. A recent study has
found increased expression of Notch2, Notch3, Hes1 and Hey1 in a wide panel of RMS
primary tumors [191]. In vitro, the genetic and pharmacological inhibition through GSI and
dominant negative MAM decreased mobility and invasiveness of RMS cells. Additional
molecular details have been provided by Raimondi et al. They found that inhibition of
Notch3 induced cell differentiation, hyper-phosphorylation of p38 and increase of p21.
Notch3 downregulation was sufficient to reduce tumor growth in vitro and in vivo [190]. All
together, these reports provide evidence for an oncogenic role of Notch in RMS and support
new therapeutic approaches targeting this pathway.
11.2.

Notch pathway in Ewing’s sarcomas
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Ewing’s sarcomas family of tumors (ESFT) arises mainly in bone and less commonly in soft
tissues [205]. The origin of ESFT is a subject of intense debate. The initial thought was in
favor of a neuroectodermal origin, but many now consider that ESFT arise from a
mesenchymal stem cell (MSC) with expression of neuroectodermal markers [206]. They are
characterized by chromosomal translocations that combine EWS and ETS family
transcription factors. Although that ESFT express Notch receptors, it has been reported that
Notch was inactive [194, 195]. Additionally, forced expression of activated Notch1, 2 and 3
induced cell cycle arrest and p21 upregulation. A different study has found a similar result:
that expression of active Notch-1 reduced the proliferation of ESFT cells [193]. These
findings suggest tumor suppressor effects of Notch signaling in ESFT.
11.3.

Notch pathway in other sarcomas

In osteosarcoma (OS), studies found overexpresssion of Notch2, Jagged1, Hey1, and Hey2
[196, 197] in comparison with normal tissue. Inhibition with GSI, CBF1 siRNA, or dnMAM
prevented the growth of OS cells and upregulated p21. These findings were replicated in a
xenograft models and suggested a contribution of Notch in the pathogenesis of OS.
Additionally, a study identified a critical role of Notch in osteosarcoma invasion and
metastasis.
Recent reports have implicated Notch pathway in two additional sarcomas. First, Notch1
knockout mice developed spontaneous angiosarcoma in the liver endothelium suggesting a
tumor suppressor effect on Notch1 [198]. Lastly, in undifferentiated pleomorphic sarcomas
(malignant fibrous histiocytoma), preliminary data suggest that the Notch pathway regulates
self-renewal of tumor initiating cells [199]. It is important to mention that before the
publication of the current work, the role of Notch in GIST was unknown.
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12. Histone deacetylase inhibitors and Notch pathway
As mentioned earlier, growing evidence showed that genetic deregulation in cancer are not
the only events that are essential for cancer formation and progression. In fact, epigenetic
modifications seem to play a central role in cancer [207, 208]. It has been widely recognized
that the remodeling of chromatin, and in particular histone modifications including
acetylation, methylation, phosphorylation, ubiquitination and sumoylation, regulate gene
expression [209]. In particular, histone acetylation and deacetylation have been shown to
play a major role in tumor formation. The two enzymes responsible for acetyl modifications
are the histone deacetylases (HDAC) that remove the acetyl-group and histone
acetyltransferases (HAT) that acetylate histone tails leading closed state chromatin in the
first case and open chromatin state in the second (Figure 5).

Figure 5. Role of histone acetyl modifications in gene expression
Reciprocal reactions, acetylation and deacetylation are catalyzed by histone
acetyltransferase (HAT) and histone deacetylase (HDAC). Acetylation of chromatin by
HAT results in open chromatine conformation and transcriptional activation of a subset of
genes while histone deacetylation by HDAC results in packed chromatin and transcriptional
repression. Figure modified from Gillet et al. Retrovirology 2007 4:18, Open Access article
distributed under the terms of the Creative Commons Attribution License.
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To date, eighteen HDAC have been identified in human and grouped into four classes. Class
I HDAC includes HDAC-1-2-3 and-8. They are highly conserved and ubiquitously
expressed. They are involved in many cellular processes such as proliferation, cell cycle,
apoptosis and DNA damage response. The Class II HDAC contains HDAC -4-5-6-7-9 and 10. They are generally expressed in a tissue-specific manner and are implicated in the
developmental process. The class III HDAC contains Sirtuins. They are broadly expressed
and have multiple biological functions, such as regulation of oxidative stress, metabolism
and aging. The class IV HDAC contains HDAC-11 [210]. Aberrant HDAC activities have
been reported in multiple human cancers. As a result HDAC are currently considered as a
target to treat cancers with epigenetic aberrations. Two HDAC inhibitors, vorinostat
(SAHA) and romidepsin are currently approved by the FDA for the treatment of cutaneous
T cell lymphoma. Although, the biologic mechanisms of action of HDAC inhibitors are not
fully understood, a large number of studies have demonstrated that HDAC inhibitors
induced cell death in a variety of tumors [211, 212]. The death-receptor extrinsic pathway as
well as the mitochondrial intrinsic death pathway have been shown to be involved in this
process [213-216]. Importantly, effects on non-histone proteins, including the chaperone
HSP90 have been characterized [217].
Suberoylanilide hydroxamic acid (SAHA) is a pan-HDAC inhibitor.

A recent study

supported that SAHA displayed antiproliferative effects in GIST cells [218]. Furthermore,
several in vitro studies have shown that diverse histone deacetylase (HDAC) inhibitors upregulated Notch1 in various neuroendocrine tumors (carcinoid tumors, pheochromocytomas,
and medullary thyroid cancers) and in parallel, decreased tumor cell growth [219-222].
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These observations support that HDAC inhibition could be an effective strategy to activate
the Notch-1 pathway and inhibit growth and hormonal secretion in NET.

13. Rational, significance of the study and specific aims

Although imatinib has dramatically changed the history of GIST treatment, it is clear
that inhibition of KIT signaling is not enough to cure patients. Primary and secondary
resistance to TKI in GIST underscore the need for new therapeutic targets beyond KIT. The
developmental pathway Notch has a critical role in cell fate, regulating cell proliferation
and differentiation. Dysregulation of the Notch pathway has been implicated in a wide
variety of cancers. Given that (i) Notch activation deregulates the morphogenesis of
mesenchymal cells in the GI track, (ii) Notch acts as a tumor suppressor in neuroendocrine
tumors, (iii) the cell of origin of GIST are the Interstitial Cell of Cajal that likely arise from a
mesenchymal origin although sharing common futures with neuroendocrine tumors, we
hypothesized that Notch pathway may have an inhibitory effect in GIST cells. In addition,
given that HDAC inhibitors have been shown to up-regulate Notch1 in neuroendocrine
tumors, and had antiproliferative effects in these cells, we hypothesized that HDAC
inhibitors may activate Notch pathway and could offer a therapeutic opportunity to treat
GIST patients, particularly after failure of tyrosine kinase inhibitors.
The present study described in this dissertation aspires to explore the role of Notch pathway
in the pathogenesis of GIST. To address this general objective, we carried out the following
research aims:
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Aim 1: To determine the impact of Notch pathway in GIST cells and to examine a
potential cross-talk between KIT signaling and Notch pathway.
Aim 2: To determine the relative prognostic potential of Notch pathway members for
predicting clinical outcome of GIST patients.
Aim 3: To Investigate the anti-tumor effects of the HDAC inhibitor SAHA and its
impact on the Notch pathway in vitro.
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Chapter 2. Material and Methods
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1. Cell culture
Three human cell lines have been use in the current study. The GIST-T1, which has
an imatinib-sensitive KIT mutation in exon 11 (V560-Y579del), was established by Dr.
Takahiro Taguchi from a patient with metastatic imatinib-naïve GIST [223]. The imatinibsensitive cell line GIST882, which has homozygous missense mutations in KIT exon 13
(K642E), was established by Dr George Demetri from a patient with primary, imatinib-naïve
GIST [20]. Imatinib-resistant cell line GIST48IM, which harbors homozygous KIT exon 11
mutations (V560D) and a heterozygous secondary exon 17 mutation (D820A), was
established by Dr. Jonathan Fletcher from a GIST patient that has progressed on IM, after
initial clinical response [224]. GIST-T1, GIST882, and GIST48IM cells were kindly
provided by Drs. Andrew Godwin (Fox Chase Cancer Center), Jonathan Fletcher (Brigham
And Women's Hospital), and Anette Duensing (University of Pittsburgh Cancer Institute),
respectively. The p53 status of these cell lines have been recently published, and suggest
that both GIST-T1 and GIST882 harbor defective p53 with homozygous deletions whereas
GIST48 cells are wildtype for p53 [225]. KIT mutations were confirmed by direct
sequencing. Potential contaminations by other cell lines were ruled out using short tandem
repeated (STR) DNA fingerprinting with an AmpFℓSTR Identifiler kit according to the
manufacturer’s instructions (Applied Biosystems). STR profiles were compared to known
fingerprints. Cells were maintained at 37˚C in a humidified incubator containing 95%
atmospheric air and 5% CO2 as described previously [226]. GIST-T1 and GIST882 cells
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Cellgro), supplemented
with 10% fetal bovine serum (FBS, PAA), and 1% penicillin/streptomycin (Cellgro).
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GIST48IM cells were maintained in Ham’s media (F-10, Thermo scientific), supplemented
with 20% FBS, 2 mM L-glutamine (VWR International), 1% penicillin/streptomycin, 0.1%
amphotericin (Amresco), 10 µg/ml gentamycin (Amresco), 0.5% MITO+ serum extender
(Becton, Dickinson and Co) and 1% bovine pituitary extract (Becton, Dickinson and Co).
The cell lines were regularly tested for mycoplasma contamination using MycoAlert
detection Kit (Lonza).

2. Drug treatment
Suberoylanilide Hydroxamic Acid (SAHA) and imatinib were purchased from the
University of Texas-MD Anderson Cancer Center Pharmacy. γ-secretase inhibitor, GSI XXI
was purchased from Calbiochem. The drugs were dissolved in DMSO (Fisher) at 10
mMol/L and filtered through 0.22-micron filters, and aliquots were stored in -20°C,
protected from light.

3. RNA purification, cDNA synthesis and real-time reverse transcription – PCR
Total RNA was isolated with RNeasy minikit (QIAgen) as described by the manufacturer.
Samples were desalted and concentrated by centrifugation columns. Omniscript Reverse
Transcription kit (QIAgen) was used to synthesize cDNA, using 2µl RT buffer, 2µl dNTP
mix, 1µl oligo-dT primer, 1µl Rnas Inhibitor, 1µl Omniscript Reverse Transcriptase,
incubated for 60 minutes at 40°C. The newly synthesized cDNA was diluted in a final
volume of 200 µl.
Real-time quantitative RT-polymerase chain reaction (RT-PCR) was performed by mixing
13µl SYBR Green buffer (Bio-Rad), 1 µl of forward and reverse primers (Invitrogen) and
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RNase-free water to a total volume of 23 µl. In total, 2 µl of the cDNA template was added
and the reaction mix heated to 95°C for 10 minutes. Amplification was carried out on an
ABI5700 (Applied Biosystems) for 40 cycles with a denaturation temperature of 95°C for 15
secondes and an annealing and extension temperature of 60°C for 1 minute. The genes
analyzed were: Notch1, Hes1 and KIT. The designed primer sequences are listed in Table 3.
The reference gene GAPDH was used for normalization. All experiments were performed in
triplicate at least three times and the results were analyzed using the Ct method and recorded
as relative expression level [227].
Genes
Forward (F)
Reverse (R)
Notch1 5'-CGGGTCCACCAGTTTGAATG-3' 5′-GTTGTATTGGTTCGGCACCAT-3′
Hes1
5'-ACGACACCGGATAAACCAAA-3' 5′-CGGAGGTGCTTCACTGTCAT-3′
KIT
5′-AGCAAATCCATCCCCACACC-3' 5′-GGCTTGAGCATCTTTACAGCGAC-3′
Table 3. List of primer sequences used for RT-Q-PCR.

4. Plasmids and retroviral constructs
A murine stem cell virus-based retroviral vector MigR1 coexpressing green fluorescent
protein (GFP) as an expression marker was used to modulate Notch signaling in GIST cells
(Figure.5) [228]. The intracellular active domain of human Notch1 (ICN1) or full-length
human Hes1 or Hes5 was inserted into the MigR1 vector. The dominant-negative Hes1
(dnHes1) and mastermind (dnMAM) were similarly generated as described previously [187,
229, 230]. All the sequences have been confirmed by sequencing. Plasmids were transfected
using lipofectamine 2000 (Invitrogen). The viruses were produced with Amphotropic
Phoenix packaging cells. This cell line is based on the 293T cell line transduced to stably
produce gag- pol, and envelope proteins.
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Xba 219

Kpn 403

Figure 6. MigR1 sequence
MSCV-IRES-EGFP retroviral
construct

5' LTR
Ori

B glI I 1406
Xho1 1412
Hpa 1 1418

AMP

Ec oR1 1424

MIGR1
6231 bp
6056
bp

HindIII 16 56

IRES

Nc o1 2017

3' LTR
GFP

Kpn1 3287
Xba 1 3103

HindII I 2832 Sa l1 2818

5. Flow cytometric analysis
For GFP analysis, adherent GIST cells were trypsinized and suspended in PBS starting 2
days from transduction. Samples were analyzed with FL-1 channel. For measurement of
KIT and Notch1 surface expression, adherent cells were resuspended in FACS buffer (PBS,
2% FBS, 0.1% sosium azide) and incubated with phycoerythrin-conjugated (PE) KIT or a
Notch1 monoclonal antibody (eBioscience) for 30 minutes. To control for nonspecificity,
GIST cells were similarly stained with a PE-conjugated isotype anti-IgG1 monoclonal
antibody (FastImmune). Transduced cells were identified as GFP+.
For cell-cycle analysis, approximately 3 × 105 cells were cultured with SAHA for 72
hours. Floating and adherent cells were collected and incubated overnight protected from
light at 4°C with 0.005% Propidium iodide (PI) and 0.1% Triton X-100 diluted in PBS. In
this assay PI binds the cellular DNA to distinguish apoptotic cell populations, and cell-cycle
phases. Apoptotic cells are identified as hypodiploid cells (sub-G1 phase), where cells with
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diploid DNA are in G0- or G1-phase, cells with supra-diploid in S-phase, and cells with
tetraploid DNA are in mitosis or G2. Events were acquired on a FACSCalibur
flowcytometer or FACSCanto II (Becton, Dickinson and Co.) and resulted were analyzed
with FlowJo v.7.6 software (Tree Star). Flow cytometic analyses were repeated at least three
times with consistent results.

6. Analysis of cell proliferation
Cell proliferation assays were performed using a Promega CellTiter 96 Aqueous
Nonradioactive Cell Proliferation Assay kit (Promega) according to the manufacturer's
instructions.

This

assay

detects

reduction

of

3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) into formazan, which
occurs in viable cells after the addition of phenazine methosulfate (PMS). The absorbance
ABS at 490nm reflects the proportion of living cells in culture. Briefly, 4000 cells/well were
seeded onto 96-well plates, and incubated at 37°C for 24 hr. Cells were treated with DMSO
or SAHA (1, 100, 500, 1000, 2000, 10000 nM in a 100 µL volume/well for 72 hr incubation,
MTS and PMS were combined and added to each well. ABS at 490nm was quantified with
Bio-Tek microplate reader A3100 (Bio-Tek Instruments) to calculate the percent viability.
Direct cell counting were done by counting Nuclei (5-25 µm) using an automated Vi-Cell
Analyzer (Beckman Coulter) as described previously or Mozi Z cell counter (Orflo) [231].
These experiments were repeated three times.

34	
  
	
  

7. Western blotting analysis
GIST cells were harvested and washed with PBS; pellets were lysed on ice for 5 minutes in
a lysis buffer with complete Protease Inhibitor Cocktail (Roche Diagnostic). The protein
concentration was measured using a Bio-Rad Protein Assay (Bio-Rad). Cell lysates were
diluted 1:2 with 10 mM DTT sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) loading buffer. Forty micrograms of protein was resolved using SDS-PAGE
gels and transferred onto polyvinylidene difluoride (PVDF) membranes by using iBlot
Blotting System (Invitrogen). Membranes were blocked with 5%, non-fat milk dissolved in
0.05% Tween-20 in PBS (PBS-T) for one hour, and washed thrice with 0.05% PBS-T for 10
minutes. The membranes were incubated for one hour with primary antibodies in 5% milkPBS-T. Membranes were washed with 0.05% PBS-T thrice for 10 minutes before incubation
with horseradish peroxidase-conjugated secondary antibodies for an hour at room
temperature as previously described [226, 230]. The primary antibodies used incubated as
follow: rabbit anti-pKIT (Tyr719) (1:1000, Cell Signaling), rabbit anti-AcH3K9 (1:1000,
Cell signaling), and rabbit anti-H3 (1:1000, Cell signaling). Actin served as control for equal
protein loading. Anti-rabbit IgG ECL antibody (1:2000, GE healthcare) was used as a
secondary antibody. Proteins bands were detected by enhanced chemiluminescence (Thermo
Scientific).Western blot analysis were repeated at least three times with consistent results.

8. Patients, tumor specimens and study approval
All GIST specimens were obtained from patients with pre-treated GIST enrolled in a
previously described IRB approved prospective phase II study of neoadjuvant and adjuvant
imatinib at MDACC [232]. The diagnoses of GIST were confirmed by experienced soft-
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tissue pathologists on the basis of clinicopathologic evaluation and marker studies.
Comprehensive patient and tumor variables were recorded and updated into a database until
December 2011. Tumor size was considered the greatest primary tumor diameter in any
dimension by computed tomography (CT). Experiments involving recombinant DNA were
approved by Institutional Biosafety Committees at MDACC and the University of Miami.
In vivo work was approved by MDACC Animal Care and Use Committee.

9. Gene expression data
For gene expression analysis, RNA from 37 GIST samples were measured using whole
human genome oligo arrays with 44-K 60-mer probes (Agilent Technology). Normalization
values (quantile intensity values) with the median of all samples have been done. Heatmap
has been generated with Matlab software (MathWorks). Some of these data have been
previously published [54].

10. Xenograft GIST mouse model
A retroviral vector encoding Firefly Luciferase and GFP was used for the transduction of
GIST-T1 cells. Stably transduced cells were sorted and tested, in vitro for light emission in
presence of D-Luciferin (Xenogen). The orthotopic xenograft model was generated by
transplantation of GIST-T1-Luc+ cells into the stomach wall of NOD/SCID IL-2-R-gamma
-/- mice purchased from the Jackson Laboratory. Methoxyflurane-anesthetized mice were
imaged weekly using a bioluminescence imaging IVIS 200 system (Xenogen).
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11. Statistical analysis
For in vitro analysis, the significance of the results was assessed using the Student-t test. All
experiments were conducted at least three times. Statistical analyses were performed using
the Prism 5 software program (GraphPad). For patient sample analysis, the relapse-free
survival (RFS) was defined as the time from surgical resection to disease recurrence; and the
overall survival (OS) as the time from surgical resection to death. To control for the known
prognostic factors, the χ2 test was used for categorical variables and the Student-t test for
continuous variables. To evaluate the association between Hes1 mRNA expression and
patient outcome, Kaplan-Meier curves were created, and log-rank tests were used to
compare RFS and OS curves among patients. To evaluate associations between the
expression of two genes, we used linear regression analyses and Pearson correlation. A
value of P<0.05 was considered to be statistically significant.
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Chapter 3. Results: Impact of Notch pathway in GIST

As previously mentioned, the cell of origin of GIST, are ICC or cells in this lineage that
represent the interface between the neural system of the gut and the endocrine system. GIST
and ICC have similar characteristics and particularly some neuroendocrine differentiation
phenotypes. We, therefore reasoned that Notch signaling may function as a tumor
suppressor for GIST, as it does for neuroendocrine tumors. We therefore examined the
impact of Notch signaling in GIST cells and tumor samples since any tumor suppressor
function might have potential benefits to treat GIST.

1. The active form of Notch1 transduction decreases GIST cell proliferation
To determine the effect of Notch signaling on GIST cells, we transduced imatinib-sensitive
GIST-T1 and GIST882 cells, and imatinib-resistant GIST48IM cells with either an empty
vector expressing GFP alone (MigR1), or co-expressing a constitutively active truncated
intracellular portion of Notch receptor 1 (ICN1). We used the percentage of GFP+ cells at
different times after transduction as an indirect measure of cell growth (Figure.7A). ICN1
expression potently induced growth arrest in the three GIST cell lines irrespective of their
sensitivity or resistance to imatinib (Figure.7B). The proportion of GFP+ ICN-expressing
cells decreased compared to GFP- cells (relative decrease of 93%, 84%, and 95% in GISTT1, GIST882, GIST48IM, respectively) 16 days after transduction (P<0.01). In contrast,
proliferation of cells transduced with control empty vector was not affected.
Since Hes1 and Hes5 are downstream target molecules of Notch signaling under the control
of the ICN/CSL/MAML complex and are essential in regulation of neuronal differentiation,
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we asked whether expression of these is sufficient to recapitulate the inhibitory effect of
ICN1 in GIST-T1 cells. To answer this question, Hes1 or Hes5 were cloned into MigR1 and
retrovirally expressed these vectors in GIST-T1 cells. Although the transduction of Hes1 and
Hes5 into GIST-T1 cells had a growth-inhibitory effect, this effect did not fully recapitulate
the growth inhibition observed with transduction of ICN-1 (Figure.7C).
To evaluate the reduced viability in GIST cells, we then examined the morphology of GISTT1 and GIST48IM after viral transduction under the microscope. Especially, we confirm
that the vector alone (MigR1) did not affect the phenotype of the cells. In contrast, the
forced expression of ICN1, resulted in cellular condensation consistent with typical
apoptotic cell death (Figure 8). The transduction with Hes5 did not appear to cause cell
death in the two cells line morphologically observed.
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Figure 7. Intracellular domain of Notch1 (ICN1) inhibits GIST cells proliferation
A. Representative histograms of GFP (marker for transduced cells) are shown in the three
GIST cell lines at days 2, 7 and 16 after transduction with MigR1 or ICN1. Three
independent experiments were performed, and one representative result is shown. GFP,
green fluorescent protein; MigR1, empty vector; ICN1, intracellular domain of Notch1.
B. Graph of the percentage of GFP+ GIST cells over time after stable retroviral transduction
of vector alone (MigR1) or containing ICN1 (normalized to day 2 after transduction). GISTT1, GIST882, and GIST48IM cells were transduced with the control vector or ICN1,
statistical differences: **P<0.01.
C. Graphs of the percentage of GFP+ GIST-T1 cells over time (normalized to day 2) after
retroviral transduction with MigR1 alone, Hes1 or Hes5, statistical differences: *P<0.05.
GFP, green fluorescent protein; MigR1, empty vector; ICN1, intracellular domain of
Notch1.
Reprinted from Carcinogenesis. Authors: Amaury G.Dumont, Yanwen Yang , David
Reynoso, Daniela Katz, Jonathan C.Trent and Dennis P.Hughes. Anti-tumor effects of the
Notch pathway in gastrointestinal stromal tumors. Copyright 2012, with permission from
Oxford University Press.

Figure 8. Morphologic features after viral transduction
GIST-T1 and GIST48IM were transduced with GFP tag vectors and the morphologic
features were evaluated by microscopy. Representative micrographs of GIST-T1 (left) and
GIST48IM (right) 6 days after transduction without sorting. Cells were transduced with the
vector alone (MigR1), ICN1 and Hes5 showing cellular condensation in presence of ICN1.
Original magnification x200. White arrow: live cells; Red Arrow: dead cells.
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2. Active form of Notch1 decreases KIT protein expression in GIST cells
To further elucidate the mechanism of growth arrest in GIST cells, and given that GIST cell
present a classical phenomenon of oncogene addiction for KIT, we investigated the effects
of ICN1 forced expression on KIT expression. We transduced the three GIST cell lines with
either empty MigR1 or MigR1 containing ICN1. Six days after transduction, we analyzed
the cell-surface KIT expression by flow cytometry using a monoclonal antibody against KIT
conjugated with phycoerythrin (PE). We observed that activation of Notch1 decreased the
KIT protein expression in the three GIST cell lines (Figure.9A and Figure.9B).
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Figure 9. ICN1 decreases KIT protein expression
A. the GIST cell lines were transduced with MigR1 or ICN1 as described above. After
transduction, KIT expression on the surface of the cells was evaluated using flow cytometry.
The KIT expression in the GFP+ (transduced cells) cells is indicated in each cell specific
gate. KIT expression was lower in GFP+ cells (transduced cells) than GFP- cells (parental
cell lines) for the constructs containing ICN1 but not for the empty vector. Three
independent experiments were performed, with similar results: one representative result is
shown.
B. comparison of the KIT expression in the GFP+ cells transduced with MigR1 alone and
ICN1 recorded in Mean Fluorescence Intensity (MFI). A PE-conjugated IgG antibody was
used as an isotype control (ISO). KIT expression was lower in the ICN1-transduced cells
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than in the vector control cells. From Dumont et al, copyright 2012, with permission from
Oxford University Press.

3. Dominant negative Hes1 transduction increases KIT protein and mRNA
expression in GIST-T1 cells
Since we found that ICN1 forced expression decreased KIT expression, we next determined
whether a specific Hes1 silencing would impact KIT expression. We blocked Hes1 by
transducing GIST-T1 cells with a construct containing dominant negative Hes1 (dnHes1) or
empty vector (MigR1). The inhibition of Hes1 via dnHes1 resulted in a two fold increase in
KIT protein level and 3 fold increase in mRNA level (Figure. 10A, 10B, and 10C).

Figure 10. Effects of Hes1 silencing on KIT expression
A. comparison of KIT expression in the vector control (MigR1) versus dnHes1 GIST-T1
cells by flow cytometric analysis.
B.Western blot analysis of pKIT showing higher protein expression in dnHes1 transduced
GIST-T1 cells. Actin served as control for equal protein loading.
C. RT-PCR analysis confirmed that mRNA KIT level was up-regulated in dnHes1 cells.
Relative KIT mRNA expression levels in relation to GAPDH mRNA levels. Statistical
difference: **P<0.01.
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1. GIST patients with high levels of Hes1 mRNA expression have better
clinical outcomes than patients with low levels of expression
The previous finding that Notch1 signaling has an anti-tumor effect in GIST cells
prompted us to determine whether baseline expression of members from this pathway is
related to relapse-free (RFS) or overall survival (OS) in GIST patients. In particular, as the
previous data showed an inhibitory effect of Notch1 in GIST cells, we hypothesized that
expression of Notch family members may be associated with improved clinical outcome in
patients. We evaluated the clinical predictive value of Notch1 and Hes1 mRNA expression
by performing quantitative RT-PCR in samples from 15 pre-imatinib GIST patients who
underwent tumor resection followed by adjuvant treatment with imatinib. Patient
characteristics are listed in Table 4.
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Table 4. GIST patient and tumor characteristics (n=15).
Statistical tests are based on P value calculation. χ2 test was used for binary/categorical
variables; t-test was used for continuous variables. From Dumont et al, copyright 2012, with
permission from Oxford University Press.

The primary tumor sites were the stomach and small bowel. The Notch1 mRNA transcript
levels were almost undetectable in all the 15 samples (Figure.11A). In contrast, Hes1 mRNA
expression was variable in the cohort (Figure.11B). We then performed a Kaplan-Meier
analysis in the patient cohort after grouping them into two categories, based on Hes1
expression. Patients with high Hes1 expression had longer RFS than did those with low
expression (median of 37 months versus median not reached at >80 months; P=0.005 (logrank test)) (Figure. 11C). However, because of the small size of the cohort and small number
of patient deaths, the difference in overall survival between the two group was not
significantly different (median not reached at >80 months in either groups) (Figure.11D).
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In the current cohort some tumors express very low levels of Notch1 mRNA while elevated
Hes1 mRNA expression. This observation may indicate that Hes1 is uncoupled from
Notch1. To clarify this point, we used additional gene expression data from 37 GIST
samples (Figure 12A). We then performed linear regression analyses of mRNA level of
Hes1 versus several Notch receptors (Notch1, Notch2, Notch4) (Figure 12B). The result
shows that Hes1 expression do not correlate with Notch receptor expression (Pearson
correlations, p>0.05). An evaluation of the Notch receptors activation at the protein level
would be essential to determine in GIST tumors if Hes1 mRNA level is strictly under the
control of the Notch pathway or alternatively may be regulated by other signaling pathways,
epigenetic regulations or non-coding RNAs.
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Figure 11. Hes1 mRNA level predicts the relapse of patients with GIST
A. Real-time RT-PCR for Notch1 and Hes1 in the 15 GIST samples. Experiments were
performed in triplicate. The data are presented as the relative expression levels using
GAPDH (2- ΔCT).
B. Kaplan-Meier analysis for relapse-free survival (RFS) in GIST patients with high versus
low Hes1 mRNA expression (n = 15; P = 0.005 (log rank test)). C, Kaplan-Meier analysis
for overall survival (OS) in GIST patients with high versus low Hes1 mRNA expression (n =
15; P = not significant (log rank test)). From Dumont et al, copyright 2012, with permission
from Oxford University Press.

.
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Figure 12. Correlation of Hes1 and Notch receptor mRNA expression in GIST tumor
samples
A. Heatmap of gene expression levels from 37 GIST human samples. Relative gene
expression are show in red (high expression) and green (low expression).
B. No statistical correlation of Hes1 mRNA level and Notch 1, 2 and 4 mRNA levels was
found, statistics are by Pearson’s correlation test.
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Chapter 4. Results: Effects of the histone deacetylase inhibitor
SAHA in GIST cells

Histone acetylation and deacetylation are processes used by the cell to modulate
transcriptional activity, cell proliferation, differentiation and apoptosis. Aberrant expression
of HDAC has been reported in a number of cancers. As a result, histone deacetylase
(HDAC) inhibition appeared to be an appealing strategy in cancer. Although a clinical
activity has been proven in particular in T-cell lymphoma, the mechanisms of action of
HDAC inhibitors are not completely elucidated. In neuroendocrine tumors, including
carcinoid tumors, pheochromocytomas, and medullary thyroid cancers, studies have shown
that HDAC inhibitors can up-regulate Notch1. In addition, a recent study provided evidence
that HDAC inhibitors, including suberoylanilide hydroxamic acid (SAHA), display
antiproliferative effects in GIST cells. SAHA inhibits class I and II histone deacetylases
[233].

We hypothesized that part of the activity of SAHA in GIST may be through

modulation of Notch pathway. Here we investigate the anti-tumor effects of the HDAC
inhibitor SAHA and the impact on the Notch pathway in GIST cells.
	
  

1. SAHA up-regulates Notch1 mRNA and protein expression
To test our hypothesis that treatment with SAHA could up-regulate Notch genes in
GIST cells, we treated these cells with SAHA by increasing concentrations for 72 hours. We
found that Notch1 mRNA expression was significantly upregulated in all three cell types
(Figure.11A). Notch1 mRNA level increase with treatment with 2 µmol/L SAHA (6 and 1.5
fold increase in GIST-T1 and GIST882 cells, respectively, P<0.05 in both cases). In
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GIST48IM, treatment with 5 µmol/L SAHA was required to up-regulate Notch1 mRNA
expression by a two-fold (P<0.05). To determine whether this increased of the Notch1
transcript level translated to Notch1 protein expression on the surface of these cells, we
performed flow cytometry analysis using a monoclonal antibody specific for Notch1 protein.
The flow cytometry analysis indicated that, at the basal level, Notch1 receptor is absent from
the surface of the GIST cells, and upregulated after treatment with SAHA (Figure.11B). A
significant up-regulation of Hes1 mRNA expression is also observed after SAHA treatment
in GIST-T1 and GIST882 (P<0.05) although this up-regulation remains small (Figure.11C).
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Figure 13. SAHA up-regulates Notch1 mRNA and protein expression
A. Quantitative RT-PCR analysis of GIST cells treated with increasing doses of SAHA for
24 hours showing Notch1 mRNA expression. The data are presented as the relative
expression levels using GAPDH as reference gene and normalized with untreated cells.
Notch1 mRNA increases after SAHA treatment. Experiments were performed in triplicate,
and repeated 3 times, the error bars represent standard deviation, statistical differences : *
P<0.05, **P<0.01.
B. GIST-T1 and GIST882 cells were treated with 2µmol/L SAHA, and GIST48IM cells
were treated with 5µmol/L SAHA. Cells were collected 48 hours after drug treatment and
evaluated for cell-surface Notch1 expression using flow cytometry. Notch1 expression
increases after SAHA treatment. Three independent experiments were performed with
similar results; one representative result is shown.
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C. Quantitative RT-PCR analysis of GIST cells treated with increasing doses of SAHA for
24 hours showing up-regulation of hes1 mRNA expression. The data are presented as the
relative expression levels using GAPDH as reference gene and normalized with untreated
cells; the error bars represent standard deviation. From Dumont et al, Copyright 2012, with
permission from Oxford University Press.

2. SAHA inhibits cell growth, activates apoptosis, and suppresses KIT
expression in GIST cells
To determine the antiproliferative effects of SAHA, we performed colorimetric MTS
assays to evaluate the GIST cell proliferation after treatment with this HDAC inhibitor.
Specifically, we treated the GIST cell lines with SAHA at clinically-relevant concentrations
for 72 hours (100nmol/L to 5µmol/L). Compared with the control group, we found a dosedependent growth inhibition in IM-sensitive GIST-T1 and GIST882 cells, and in IMresistant GIST48IM cells (Figure.12A).
To confirm that the antiproliferative effect of SAHA on GIST cells is related to apoptosis,
we performed cell cycle analysis of detached and attached cells treated with SAHA. We
found a dose-dependent increase in the number hypodiploid sub-G1 cells for all three cell
lines (Figure.12B). Notably, in GIST-T1 cells, treatment with 2 µmol/L SAHA resulted in a
25-fold increase in the sub-G1 population over that in cells treated with control DMSO. In
GIST48IM cells, the effect of treatment with 2 µmol/L SAHA was minimal and treatment
with 5 µmol/L was required to achieve a 2.5-fold increase of the sub-G1 population
compared with control cells.
In addition, to determine whether SAHA affects KIT expression, we first investigated the
effects of treatment with SAHA on KIT mRNA level in GIST cells. To prevent the
confounding late effects of apoptosis on KIT expression, we performed quantitative RTPCR analysis to measure the KIT mRNA expression in the three GIST cell line at an early
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time point (24 hours). In agreement with published findings, KIT mRNA level decreased in
a dose-dependent manner with treatment with 2 µmol/L SAHA (85% and 62% in GIST-T1
and GIST882 cells, respectively). In the imatinib resistant GIST 48IM, treatment with 5
µmol/L SAHA down-regulated KIT mRNA expression by 73% (Figure. 12C). In contrast,
treatment with imatinib did not decrease KIT mRNA level compared with DMSO control.
Furthermore, to determine whether the loss of KIT mRNA expression affected KIT
protein expression and activation, we performed Western blot and flow cytometric analysis
of the three GIST cell lines after 48 hours of treatment with SAHA. The treatment resulted
in a decrease of total KIT expression and a complete inhibition of phosphorylated KIT in the
three cell lines (Figure.12C). As expected, we observed parallel dose-dependent
hyperacetylation of histone H3 at lys9 in the three cell lines after HDAC inhibitor treatment
(Figure.12C).
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Figure 14. Dose-dependent decrease in cell viability, increase in apoptosis, and
downregulation of KIT expression in GIST cell lines following exposure to SAHA
A. Exponentially growing GIST cells were exposed to varying concentrations of SAHA.
Cell proliferation was assessed using an MTS assay 3 days after drug exposure. Points
represent mean absorbance of triplicate wells relative to DMSO vehicle controls; bars,
standard deviation.
B. Results of cell-cycle analysis using propidium iodide (PI) staining and flow cytometry:
GIST cells were incubated with SAHA at the indicated concentrations for 72 hours.
Proportion of apoptosis cells estimated by the amount of the hypodiploid DNA peak
(sub-G1 populations) indicated by the arrows. The experiments were repeated on three
separate occasions with similar results.
C. Quantitative RT-PCR analysis of KIT mRNA expression in GIST-T1, GIST882, and
GIST48IM cells 24hours after increasing doses of SAHA. The histograms show the
changes in KIT mRNA expression after normalization with GAPDH expression in
triplicate wells; Bars, standard deviation, statistical differences: **P<0.01. GIST cells
were treated with SAHA 2 µmol/L for 48 hours and evaluated for cell-surface KIT
expression by flow cytometry. The Western blot analysis shows the level of
phosphorylated KIT (P-KIT) and acetylated Histone H3 (Ac-H3) in GIST cells after
48hours of SAHA treatment. Actin served as control for equal protein loading. Three
independent experiments were performed: one representative result is shown. IM,
imatinib; ISO, isotype control; Ctr, DMSO control. . From Dumont et al, Copyright
2012, with permission from Oxford University Press.

3. Inhibition of Notch pathway partially rescues GIST cells from the effects
of SAHA treatment
Given that the treatment with HDAC inhibitors potentially affects the expression of
hundreds of genes, we performed a rescue assay to elucidate the relative contribution of
upregulation of Notch1 expression to the mechanism of action of SAHA in GIST cells. We
transduced GIST-T1 cells with dominant negatives dnHes1 and dnMAM and examined
cells’ viability and KIT expression. To avoid counting dead or dying cells, we assessed cell
growth by counting the nuclei after chemical lysis of the plasma membrane. After 72 hours
of treatment with 1 µmol/L SAHA, we observed a significant difference between growth of
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cells transfected with dnHes1 and vector control (P<0.001) but not with the dnMAM
construct (Figure.5A). Pharmacological inhibition of Notch activation by a γ-secretase
inhibitor (GSI XXI) showed a partial rescue of the effect of SAHA in GIST-T1 and
GIST882 cells. Indeed the addition of GSI XXI decreased the inhibitory effect of SAHA
alone (P<0.05) (Figure 5B).
We then studied the KIT cell surface expression after SAHA treatment in cells transduced
with these constructs. Down-regulation of KIT cell surface expression was partially
abolished by dnHes1 expression. In contrast, dnMAM did not rescue the KIT protein
expression after the treatment (Figure.5C). After SAHA treatment, in presence of dnHes1, a
partial rescue of the KIT expression was found by flow cytometry and western blotting
(Figure13.C and Figure.13D).
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Figure 15. Dominant negative Hes1 and γ-secretase inhibitor treatment partially rescue
the cell growth from SAHA treatment
A. Growth curve of GIST-T1 cells transduced with dnHes1, dnMAM, and vector alone after
DMSO control and 1 µmol/L SAHA. The numbers of cells were assessed by automated ViCELL Analyzer. DnHes1 partially rescues the cell growth, while dnMAM does not. Data are
presented as the mean of three independent experiments +/- standard deviation, statistical
differences: *P<0.05.
B. Growth curve of GIST-T1 and GIST882 cells after treatment with SAHA 2 µmol/L alone,
GSI XXI 100nmol/L alone or in combination of the two drugs. The numbers of cells were
assessed by Moxi Z cell counter. Data are presented as the mean of three independent
experiments +/- standard deviation, statistical differences: *P<0.05.
C. GIST-T1 cells transduced with a MigR1, dnHes1 and dnMAM cells were treated with 2
µmol/L SAHA. Cells were collected 48 hours after drug treatment and evaluated for cellsurface KIT expression using flow cytometry. The KIT expression is rescued by dnHes1 but
not dnMAM. Three independent experiments were performed with similar results.
D. Western blots analysis showing levels of phosphorylated KIT (P-KIT), total Histone H3
(H3), and acetylated Histone H3 (Ac-H3) in GIST-T1 cells after 48 hours of SAHA
treatment. Actin served as control for equal protein loading. Modified from Dumont et al,
Copyright 2012, with permission from Oxford University Press.
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Chapter 5. Discussion, future directions and conclusion
Despite the major success of imatinib in the treatment of GIST, acquired resistances
mainly caused by secondary mutations of KIT remain a major clinical challenge. Currently,
second-generation tyrosine kinase inhibitors are used after failure of imatinib, but these
drugs provide little clinical help prior to disease progression. For those patients, the need for
new therapeutic strategies beyond KIT inhibition is critical.

1. Impact of Notch1 in GIST
Notch signaling pathway is an evolutionary highly conserved pathway that regulates
fundamental cellular functions in multicellular organisms, particularly proliferation, stem
cell maintenance and differentiation. Extensive studies have shown that Notch signaling
regulates cell fate decisions in the intestinal epithelium as well as neural crest-derived tissue
via Hes family member transcriptional repressors. In cancer, where cells fail to regulate their
growth within normal homeostasis, studies have implicated the Notch pathway in the
initiation and progression of different hematological malignancies and solid tumors.
However, prior to our current work the role of Notch pathway in GIST has not been studied.
In the present study, it was established that GIST cell lines and patient samples had very
low mRNA Notch1 expression. By constitutively actived Notch1, by viral transduction of
the intracellular domain of Notch1, in three human GIST cells we observed a growth
inhibition in GIST cells with diverse KIT mutations and sensitivities to imatinib. It was
reasonable to speculate that the growth inhibition caused by ICN1 in GIST cells resulted
from the depletion of KIT. As a result, we demonstrated that KIT expression was downregulated in response to Notch1 activation. Interestingly, we found that transduction with a
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dominant negative of Hes1 increased KIT expression in GIST-T1 cells. Taken together, our
work suggests a negative interaction between the Notch1 and KIT pathways in GIST. To
determine the effect of downstream target genes of Notch signaling on GIST biology, we
tested the effects of Hes1 and Hes5 on GIST-T1 cells. We found that Hes1 or Hes5 alone
decreased cell proliferation but did not fully recapitulate the profound effect of ICN1 on
growth inhibition in GIST-T1 cells. This finding may indicate that, although Hes1 and Hes5
have an inhibitory effect, they may have additive effects, or may not be the only downstream
targets of ICN1 implicated in this observation.
To further investigate the mechanism by which ICN1 decreases KIT expression, we
performed an in silico analysis of the KIT promoter sequence up to 1306bp. This analysis
revealed the presence of two N-box consensus sequences (CACNAG) at -738,-733bp and 520,-515 bp that constitute binding site for Hes family members (Figure.14).

Figure 16. N-Box consensus sequences found in the KIT promoter region
From Dumont et al, copyright 2012, with permission from Oxford University Press.

Additionally, epigenetic modifications and microRNA interactions may modulate the level
and stability of KIT mRNA in a Notch-dependent manner. Further studies are needed to
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clarify the mechanisms and effectors of Notch-mediated growth inhibition and
downregulation of KIT expression in GIST cells.
As previously mentioned, one of the more common cytogenetic aberrations found in GIST is
the loss of the chromosome 1p region (between 1p36 and 1p13). This deletion is associated
with aggressiveness in GIST and is less frequently found in other sarcomas such as
leiomyosarcomas. Interestingly, this region contains the hes2, hes3, hes4 and hes5 genes. It
was proposed that the deletion of chromosome 1p plays an important role in GIST
progression by the loss of unknown tumor suppressor genes. Considering our results, we
envisage that these genes may include Hes family members.
Having found that Notch1 activation induces growth arrest and downregulates KIT
expression in GIST cells, we next examined whether difference expressions of Notch
signaling members were associated with differences in clinical outcome in patients. Using
15 pre-treated GIST patient samples we found that the level of Hes1 mRNA expression was
a prognostic factor for relapse in our cohort. Larger studies with proper controls are needed
to confirm the prognostic role of Hes1 in GIST.

2. Activity of SAHA in GIST cells

SAHA is an HDAC inhibitor that has been shown to cause in vitro growth arrest, apoptosis,
and to promote differentiation, as well as to exhibit antitumor activity in patients by reinducing expression of tumor suppressor genes and downregulating expression of
oncogenes. To use clinical relevant concentration of SAHA in our study, we performed a
review of the pharmacokinetic data available. As we recently pointed out in the journal
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Cancer Research, the utilization of correct doses for in vivo studies is critical [234]. In the
case of SAHA, phase I studies have shown that the drug has a linear pharmacokinetic, an
apparent half-life around 100 minutes and an acceptable bioavailability of 40 to 50%. The
Cmax after multiple oral administrations ranged between 1.35 and 2.04 µM [235-237].
Our current study demonstrated that the HDAC inhibitor SAHA can upregulate Notch1
expression in GIST cells as it was previously observed in neuroendocrine tumors. In our
work, we established that treatment with SAHA at a concentration of 2 µM decreased
viability, induced apoptosis, increased Notch1 expression and reduced KIT expression in
two cell GIST lines. Interestingly, the third cell line GIST48IM that is resistant to IM
appeared also to be more resistant to SAHA. This apparent cross resistance may reveal drug
efflux, epigenetic alterations, resistance to apoptosis or pro-survival mechanisms. In this
case, combination therapy with DNA demethylating agents or Bcl-2 inhibitors, for example,
could be important in achieving efficacy in GIST.
The mechanism of action of HDAC inhibitors in GIST cells remained controversial. A
previous study demonstrated that HDAC inhibitors could deregulated the heat shock protein
90 (Hsp90), a KIT protein chaperone, and proposed that HDAC inhibitors may silence KIT
expression via increase of acetylation of HSP90 and a subsequent disruption of KIT at the
protein level. However, we found in the current study that downregulation of KIT protein
expression could be the result of the strong decrease of the KIT mRNA level observed by QRT-PCR. Although both events,(the decrease of KIT mRNA level and the loss of HSP90
chaperone activity) may contribute to the effects of SAHA on GIST cells, we did not
quantify the respective contributions of these mechanisms. Nevertheless, the profound
decrease in KIT mRNA transcript level that we observed seems to point out a major
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transcriptional effect rather than a post-translational regulation. To confirm that SAHA’s
effect is partially due to its upregulation on the Notch1 pathway, we showed a partial rescue
of cell growth and KIT expression after Notch inhibition with dnHes1 and the γ-secretase
inhibitor XXI.

3. Future directions
In Chapter 3, we have demonstrated that Notch 1 activation decreases cell growth. However
additional work is required to better understand this observation. The decrease in cell growth
can be the result of apoptosis, necrosis, quiescence or senescence. To answer this point a
deeper analyze of apoptosis, senescence and differentiation of the GIST cells after forced
expression of Notch1 would be important. In particular, a recent study from Kannan et al,
demonstrated that Hes1 interacted with the Poly ADP-ribose polymerase-1 (PARP1) in a
cell type-specific manner, ultimately resulting in apoptosis [186]. It would be interesting to
observe if such a PARP1/Hes1 interaction exists in GIST cells.
Our gene expression analysis on 37 GIST human samples may indicate that Hes1 is not
under the strict control of Notch1 as they are not in the same cluster in the Heatmap figure
12. Nevertheless, it is important to mention that gene expression and protein level rarely
correlate. Only an immunohistochemistry analysis on tumors samples would address this
point. The direct demonstration of the activation of the Notch receptors by showing an
increase of the intracellular domains of those receptors would be critical.
Our study established that Notch 1 expression results in decreased expression of KIT
receptor. However, the mechanism is not completely understood. Our data suggest that the
downregulation of KIT protein is the result of a decrease of KIT mRNA level, but a rigorous
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demonstration would be required. The decrease of the mRNA level could be the result of a
reduction in transcription rate or mRNA stability. To evaluate the transcription rate, a
nuclear run-assay with radioactive nucleotides would be the best method. To test the
degradation rate, a study of the mRNA half-life in presence of a transcription inhibitor such
as actinomycin D could be proposed.
We found two consensus sequences for Hes family members in the promotor region of KIT.
To establish definitely whether Hes family members binds these two putative sites, the gold
standard would be a chromatine immunoprecipitation (chip) assay using specific primers for
these binding sites. Alternatively, a mutagenesis site directed assay and reporter luciferase
assay could be pertinent.
In the current work, we studied the cross-talk between KIT and Notch exclusively in GIST
cells. Investigating whether other tumors have similar negative relationship in tissues where
KIT is highly expressed, such as hematopoietic stem cells, melanocytes, mast cells, and
germ cells, would be relevant. Growing evidence points to the limitations of in vitro work,
in particular, in conventional cell line culture. To address this concern, the impact of Notch
pathway in GIST could be evaluated with an in vivo model that includes the tumor
microenvironment. During the time of this study, such model was not available.
Consequently, we tried to establish a clinically relevant animal model for GIST.

We

generated an orthotopic xenograft model by a surgical inoculation of human GIST-T1 cells
into the gastric wall of NOD/SCID Il-2-R-gamma-/- mice. GIST-T1 cells were stably
transduced to express the luciferase gene in order to allow non-invasive bioluminiscence
imaging. The xenografts were established in twelve mice by injecting 1 × 106 cells and
resulted in a tumor take in nine mice (75%) without dissemination of cells into the abdomen
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due to the procedure (Figure 17). The luciferase signal increased until the week 5 after
injection and reached a plateau. Paradoxically, the cells were not able to growth further, and
invasion was not observed. As a resulted, this model did not completely mimic aggressive
human GIST and has limited interest. An evaluation of other GIST cell lines available would
be relevant. The utilization of a knock-in mouse GIST model harboring KIT mutation could
be an alternative to the xenograft model.
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A

B

C

Figure 17. Orthotopic mouse model of GIST
A. Mice were anesthetized and a sub-line of GIST-T1 that express firefly Luciferase was
implanted into the gastric wall. B. Representative image with stereo microscope.
C. Mice were monitored using bioluminescence imaging (IVIS) following intraperitoneal
injection with D-luciferin. Representative images 5 weeks after implantation of luciferaseexpressing GIST-T1 cells into the gastric wall.

We have demonstrated in the chapter 4 that SAHA treatment suppresses oncogenic KIT and
decreased the viability of the cells. Mechanistically, treatment with SAHA reduced KIT
mRNA levels and up-regulated Notch1 mRNA levels. To confirm the functional activity of
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SAHA-induced Notch1 a luciferase reporter assay incorporating binding sites of
downstream effectors of Notch1 would be required.
A more comprehensive evaluation of other HDAC inhibitors in GIST, especially more
selective HDAC inhibitors, would be important to determine if the phenomena described in
the current study is also valid for other members of this therapeutic class.
Although HDAC inhibitor treatment resulted in promising in vitro data, results from clinical
trials in solid tumors have been disappointing. In GIST, the result from a Phase 1 trial of
imatinib plus panobinostat (LBH589) in third line therapy has been recently presented
during the American Society of Clinical Oncology annual meeting [238].

In the 12

extensively pretreated patients receiving the treatment, limited activity on PET scan were
observed with one partial response and eight stable disease.

4. Conclusion
In conclusion, in this study, we demonstrated that active form of Notch1 has a growthinhibitory effect on GIST cells. Furthermore, in our small cohort, high mRNA Hes1
expression levels are associated with improved relapse-free survival in patients with resected
GIST and may be important prognostic markers for GIST. The up-regulation of Notch1 may
be a therapeutic opportunity for GIST patients as our data suggest that treatment with SAHA
could increase the mRNA and protein Notch1 expression. Notch1 pathway activation with
HDAC inhibitors may represent a novel strategy for treatment of GIST, especially after
tyrosine kinase inhibitor failure. Altogether, our findings provide evidence for a direct
negative regulation of KIT by Notch1 pathways and support a tumor suppressor of Notch1
pathway in GIST. Future studies are needed to characterize the mechanism underlying the
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crosstalk between KIT and Notch pathways. Nevertheless, our study suggests that the Notch
pathway represents a potential therapeutic target in GIST. In the last decade, despite its
rarity, GIST has been at the center of a paradigm shift in the treatment of solid tumors. We
hope that discoveries derived from GIST studies will persist to extend beyond this disease to
influence the oncology field in general.
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APPENDIX

A non-random association of gastrointestinal stromal tumor (GIST) and
desmoid tumor (deep fibromatosis)
This appendix describes a supplementary work published in the Annals of Oncology [93].
As patients with GIST are living longer, their risk of developing other malignancies is
evaluated and reported in the literature. However, the associations between GIST and other
tumors remain unclear. Most reports described single cases or very small series of patients
from single institution. GIST have been reported to coexist with gastric, breast, prostate,
renal, esophagus, colorectal, lung and pancreatic carcinomas; carcinoids; lymphomas and
melanomas [239, 240]. Additionally, two case reports of a patient with desmoid tumors (DT,
also known as deep or aggressive fibromatosis) and GIST in the same anatomic location
were recently reported [241, 242]. Interestingly, DT are very rare sarcomas with a tendency
for slow, local infiltrative growth where an embryonic conserved signaling pathway, the
Wnt/β-catenin signaling pathway appears to play an central role in the tumor formation.
Like the Notch pathway, development studies on Drosophila have described the phenotype
‘wingless’ and demonstrated that this pathway was involved in the establishment of the
body axis as well as the development of many organs.
In DT nuclear expression of β-catenin has increasingly been used in the differential
diagnosis of spindle cell neoplasms, particularly in the abdomen [243]. Mutations in the
CTNNB1 gene, which codes for β-catenin, have been found in the majority of DT patients,
with most mutations occurring in exon 3 [244-246].
DT do not metastasize but can cause significant morbidity through their locally destructive
effects. Prior trauma, such as previous surgery, is known to increase the risk of sporadic and
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FAP-associated DT [247, 248]. Complete surgical resection with a wide margin and/or
radiation therapy constitute the mainstay of resectable DT therapy, while chemotherapy,
anti-inflammatory agents, tyrosine kinase inhibitors are all treatment options for locally
advanced DT.
Anecdotal reports of individuals with GIST and DT led us to evaluate a larger cohort to find
patients with both tumors, in order to gain insight into whether their simultaneous
occurrence is a coincidental event.

Material and Methods
Patients and tumor tissues
A retrospective analysis was performed from the patient records between 1978 and 2008 at
The University of Texas - MD Anderson Cancer Center, Helsinki University Central
Hospital, Fox Chase Cancer Center, Oregon Health & Science University Knight Cancer
Institute, Cleveland Clinic, Istituto Nazionale dei Tumori, Prince of Wales Hospital, H. Lee
Moffit Cancer Center, the Armed Forces Institute of Pathology, and Memorial SloanKettering Cancer Center using a protocol approved by the respective Institutional Review
Boards. We founded 28 patients with both GIST and DT. Clinical characteristics and
formalin-fixed, paraffin-embedded GIST and DT specimens accrued were retrieved.
Specimens were further screened and evaluated by experienced soft-tissue pathologists at
MD Anderson or Fox Chase who confirmed DT and GIST histology. Demographic and
clinical information, including treatment, histology and outcome related variables were
tabulated for analyses.
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Genomic DNA isolation
When tissues were available genomic DNA was extracted from 10-µm-thick formalin-fixed,
paraffin-embedded tissue sections cut from blocks with at least 80% tumor using the
QIAamp DNA mini kit (Qiagen, Valencia, CA) or the Easy-DNA kit (Invitrogen, Carlsbad,
CA).

Analysis of KIT, PDGFRA and CTNNB1 mutations
Polymerase chain reaction (PCR) amplification of DNA for KIT exons 9, 11, 13 and 17;
PDGFRA exons 12, 14 and 18 and CTNNB1 (β-catenin) exon 3 was performed.. Each PCR
amplification was performed in a 50-µl volume containing 10 ng of genomic DNA, 15 µM
concentrations of each primer, 0.2 mM deoxyribonucleotide triphosphate, 5 µl of 10 x
reaction buffer, 2.5 mM MgCl2 and 1 unit of AmpliTaq Gold DNA polymerase (Applied
Biosystems). The KIT and PDGFRA primers were previously published [108, 249]. The
PCR conditions were as follows: 30 sec at 94˚C; 30 sec at 52˚C and 1 min at 68˚C for 36
cycles, followed by 10 min extension at 68˚C. The primers for CTNNB1 exon 3 primers
were as follows: forward: 5’-TTTGATGGAGTTGGACATGG-3’ and reverse: 5’CTGAGAAAATCCCTGTTCCC-3’. The PCR conditions for CTNNB1exon 3 were as
follows: 30 sec at 94˚C; 30 sec at 55˚C and 1 min at 68˚C for 36 cycles, followed by 10 min
extension at 68˚C. PCR products were analyzed in by gel electrophoresis and purified using
a Qiaquick PCR purification kit (Qiagen). Direct sequencing was carried out from both
directions using a BigDye Terminator v3.1 cycle sequencing kit on an ABI PRISM 3100
genetic analyzer (Applied Biosystems). The National Center for Biotechnology Information
Basic Local Alignment Search Tool was used to analyze both strands to identify mutations.
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Statistical analysis
A standardized incidence ratio (SIR) represents a comparison between observations and
expectations. This ratio is calculated by the number of events observed divided by the
number of events expected. In this study, SIR was calculated to compare the incidence of
DT in patients with GIST to the incidence of DT in the general U.S. population from 2000 to
2008 [250]. We calculated the 95% CIs of SIRs using the formula proposed by
Vandenbroucke [251]. Overall survival was calculated as the time between the date the first
neoplasm was diagnosed and the date of death or the last known date at which the patient
was alive. Survival curves were estimated using the method of Kaplan and Meier method
and the log-rank test.

Results
The 28 patients harboring GIST associated with DT were identified as follows: MD
Anderson Cancer Center (cases 1-4), Helsinki University Central Hospital (cases 5-6), Fox
Case Cancer Center (cases 7-9), Oregon Health & Science University Knight Cancer
Institute (case 10), Cleveland Clinic (case 11), Istituto Nazionale dei Tumori (case 12),
Prince of Wales Hospital (case 13), H. Lee Moffit Cancer Center (cases 14-16), the Armed
Forces Institute of Pathology (cases 17-23) and Memorial Sloan-Kettering Cancer Center
(cases 24-28). Table 5 shows the clinical characteristics of this patient population, which
included 19 men (68%) and 9 women (32%) whose ages ranged from 34 to 88 years.
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Case no.

Age

Sex

Primary
location of
GIST

1

62

M

Gastric

yes

2

67

M

Gastric

yes

3

50

M

Gastric

no

4

45

F

Omentum

yes

5

39

F

Jejunum

yes

6

62

F

Gastric

yes

7

59

F

Gastric

yes

8

62

F

Jejunum

yes

9

74

M

Gastric

yes

10

75

M

Gastric

11

88

F

12

61

M

13

62

14

Imatinib

KIT or
PDGFRA
Mutations
(GIST)

Site of DT

B-Catenine
Mutations
(Desmoid
Tumor)
CTNNB1

Interval
between
GIST and
DT (months)

Outcome

KIT mutation
exon 11: V560D
KIT exon 11
mutation :
deletion

Perigastric peripancreatic

exon 3:Wt

39

Gastric

exon 3:T41A

35

ND
KIT mutation
exon 11: D579del

Retrogastric
Colon

exon 3 : Wt

39

WT
KIT exon
11mutation: del
Lys 550-Glu556+
insLeu
KIT exon
11mutation:
W557-K558del
KIT exon 11
mutation : del
556-573

Small bowel

exon 3 : Wt

32

NED: February
2009
NED: December
2007
AWD: January
2008
Died on January
2009

30

Alive: May 2010

Small bowel

exon 3 : Wt
exon 3: T41A
missense
mutation

42

Alive: May 2010

Small bowel

exon 3: S45P

16

Alive: May 2010

Omentum

exon 3: T41A

25

Alive: May 2010

no

ND
PDGFRA exon
18 mutation:
D842V

Peripancreatic

ND

0

Small intestine

no

WT

Abdominal wall

exon 3: Wt

-7

NED: January
2005
NED: January
2003

Gastric

yes

Abdominal wall

ND

28

Died: July 2004

M

Gastroduodenal

yes

ND
KIT exon
11mutation:
deletion

Infrapyloric
mesenteric

exon 3: T41A

36

42

F

Jejunal

yes

ND

Pelvic

ND

21

Died: March
2010
NED : October
2006

15

71

F

Gastric

yes

Caudate lobe liver

ND

24

Alive : May 2010

16

52

M

Pelvic

yes

ND
KIT exon 9
mutation

Mesenteric

ND

30

Alive : May 2010

17

53

M

Gastric

no

ND

Spleen

ND

33

ND

18

75

M

Gastric

no

ND

Mesenteric

ND

0

ND

19

65

M

Gastric

no

ND

Mesenteric

ND

0

Died: July 1988

20

70

M

Gastric

no

ND

Thigh

ND

191

21

66

M

Gastric

no

ND

Mesenteric

ND

0

22

42

F

Small intestine

no

ND

Mesenteric

ND

0

23

40

M

Small intestine

no

Mesenteric

ND

12

24

34

M

Proximal
Jejunum

no

ND
KIT exon 9
mutation : 502-3
AY duplication

NED: March 2003
NED: January
2003
Alive: January
2004
No follow up
since 1986

Terminal ileum

ND

19

NED: Oct 2009

25

58

M

Gastric

yes

Mesenteric

ND

62

AWD: May 2010

26

58

M

Gastric

yes

Mesenteric

ND

30

AWD: May 2010

27

54

M

Gastric

yes

ND
KIT exon 11
mutation : Del
(6aaDEL 552-7
MYEVQW)
KIT exon 11
mutation : Del
(557-8 WK del)

Small
bowel/mesentery

ND

33

NED: April 2010

28

68

M

Small intestine

yes

ND

Proximal jejunum

ND

6

Alive: April 2010

Right rectus
abdominis

0

NED: August
2009

Table 5. Patient and tumor characteristics
Summary of the 28 patients who developed GIST and DT.GIST, gastrointestinal stromal
tumor; DT, desmoid tumor; Wt, wild type; ND, no data; NED, no evidence of disease;
AWD, alive with disease. Modified from Dumont et al, Copyright 2012, with permission
from Oxford University Press.
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The majority of patients had sought medical advice because of vague symptoms such as
epigastric pain, nausea or abdominal discomfort. Interestingly, no cases with a family
history of FAP were observed.
In 21 cases (75%), GIST was diagnosed before DT. The average time between these
diagnoses was 30 months (range, 6 months-16 years). In 6 cases (21%), both tumors
presented synchronously and in 1 case (case 11; 4%), GIST was diagnosed after DT. The
primary GIST tumor site was gastric in 17 cases (60%), small intestinal in 9 cases (32%) and
pelvic or mesenteric in 1 case each (4%). DT involved the extremity in only 1 patient, who
developed DT of the thigh 16 years after treatment for gastric GIST. In 3 patients (10%), DT
developed in the surgical incision site and mimicked a recurrence of GIST. 17 patients
(60%) were treated with imatinib. Ten cases (10, 11, 16-23; (36%)) developed a GIST
before imatinib therapy was available. A strong family history of GIST (father, brother and
aunts) was found in case 4, caused by a rare germline mutation of KIT that was previously
described [252].
Interestingly, there are reports in the literature investigating the use of imatinib for treating
DT. Case reports have described responses to imatinib, and a series of 19 patients with DT
showed a partial response in 3 patients [253-255]. In our series, patient number 2, a 67-yearold man, received imatinib at 400 mg/day for gastric GIST and developed a DT on the
posterior wall of the gastric antrum 35 months after the first diagnosis. His dose of imatinib
was increased to 800 mg/day, resulting in a partial response in both tumors (Fig.ure 18).
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Figure 18. Partial response observed by Computed Tomography in GIST and DT after
treatment with Imatinib at 800 mg/day.
Arrows indicate tumor localization. From Dumont et al, Copyright 2012, with permission
from Oxford University Press.
The frequency of mutations in KIT and PDGFRA in GIST was similar to that
previously observed in large cohorts of patients with GIST [256]. KIT was mutated in 11
cases of 14 (79%), of which 9 cases (64%) were in exon 11 and 2 cases (14%) in exon 9.
PDGFRA was mutated in 1 case (7%). Two cases (14%) lacked mutations in KIT or
PDGFRA (wild type).
β-catenin is commonly deregulated in DT indeed mutations in the CTNNB1 gene have been
identified with a prevalence of 85% in a large cohort of patients with DT [245]. In our
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samples available for genotyping, CTNNB1 was mutated in 5 cases (50%) in exon 3 (4 type
41A and 1 type 45F; Table A1).
The annual incidence of GIST in the United States is estimated to be 10-15 cases per million
[257], while the annual incidence of DT is 2-4 cases per million [258]. The expected number
of DT events in patients with GIST was calculated by applying the DT rate for theoretical
GIST population in the US. To assess the SIR, only cases from the US from 2000 to 2008
were used. In this case series, 13 patients were diagnosed with GIST and DT in the US
between 2000 and 2008. This number was compared to 0.16, an estimated number of
expected cases assuming the independence of events. The estimated risk of developing DT
was significantly higher (SIR = 82; 95% CI, 44-133) in GIST patients than in the general
population.

Discussion
To our knowledge, this study was the first to report a series of patients with coexisting GIST
and DT. This relationship raises the questions about of a potential link between these two
neoplasms and the possibility of a cancer predisposition syndrome. In our patients who
developed both tumors there were more men than women (19 vs 9). Accepting the
possibility of a selection bias in this population, this gender distribution differs from that
reported in previous GIST and DT studies. The incidence of GIST is equal among men and
women GIST, and in DT a female predilection is suggested; with a female to male ratios
commonly ranged between 1.4 and 1.8 [259, 260]. Furthermore, the peak incidence of DT
has been reported as 25-35 years; however, in our case series, DT occurred at an average of
59 (range 34-88 years) [258, 260]. Statistical study on this limited population need to be
interpreted carefully but because these tumors are very rare, the size of this series and the
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SIR suggest a strong nonrandom association between the distinct tumors. At this stage, we
can only speculate about this association.
Although the risk of developing both tumors appears extremely rare, this possibility should
be considered when the patient has an occurrence of either of these tumors. There are no
data to support a genetic predisposition syndrome, nevertheless, a germline mutation might
underlie predisposition for these 2 tumors.

We noted that most of the patients had

abdominal surgery to remove their GIST and then developed a DT. It is possible that in
some of the cases, the surgical trauma latter provokes the desmoid growth. No history of
FAP was observed in our patients that could explain the increase of risk for developing a
postoperative DT. The treatment with imatinib does not appear to play a role in the
development of DT, because several cases in our series were not treated with imatinib.
Interestingly, there are reports in the literature investigating the use of imatinib for treating
DT. Case reports have described responses to imatinib, and a series of 19 patients with DT
showed a partial response in 3 patients.[253-255] Another possibility is that GIST patients
under physical and radiological surveillance are more likely to have DT detected compared
to “normal” population. Finally, it is interesting to speculate that circulating stem cell factor
(KIT ligand) or platelet-derived growth factor in patients with GIST could stimulate the
growth of DT. Indeed, a cross-talk between the KIT and Wnt signaling pathways has been
recently described in mast cell leukemia [263]. In this model, nuclear accumulation of βcatenin was increased by a gain-of-function mutation of KIT [261].
In this clinical and translational study, we show statistical evidence that there is a
nonrandom relationship between the concomitant development of GIST and DT. Excluding
a recurrence of GIST is fundamental for the clinical management of a patient that could
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potentially still benefit from targeted therapy, such as imatinib. Further investigation is
needed to establish the link between these tumors and to evaluate possible risk factors for
their association.
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